• Full year 2023 total revenues increased by 19% to US$245.3 million
• Record fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 million
• Strong start to Joenja® (leniolisib) launch with 81 patients on paid therapy in the U.S. nine months following launch and full year 2023 revenues of US$18.2 million
• Overall cash and marketable securities increased to US$215.0 million at the end of 2023 from US$208.7 million at the end of 2022
• Progressed leniolisib development for APDS in additional geographies and for pediatric patients, and leniolisib indication expansion to primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kδ signaling
• 2024 total revenue guidance of US$280 million – US$295 million (14% – 20% growth)

Pharming hosted a presentation for analysts and investors at 13:30 CET/08:30 EDT on March 14, 2024 (view webcast). To participate in the conference call, please register in advance using this link. 

Please note, the Company will only take questions from dial-in attendees.